Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05315596
Other study ID # JenaUH_pain
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date February 1, 2022
Est. completion date December 31, 2030

Study information

Verified date March 2022
Source Jena University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Little is known about pain-related outcomes experienced by patients in the first few weeks after surgery, once they are discharged from hospital. This study aims to characterize pain, pain-related interference, and early neuropathic pain in the sub-acute phase after surgery.


Description:

A high proportion of patients experience moderate to severe pain after surgery. However, most of the knowledge about this comes from studies where patients are evaluated in the hours and up until the first postoperative day. Alternatively, patients are assessed several months (eg 3 or later) after surgery, to evaluate the development of chronic pain related to surgery (CPSP) and most patients do not develop CPSP. This study aims to learn how patients recover concerning pain and function once they return home after surgery. How long is it before they can resume their daily activities and to do so in comfort? Do they take treatment for pain? Do they have pain restricted to the surgical incision or it is more widespread? There is little knowledge as to whether there are signs of nerve injury in the days close to surgery. This type of pain might lead to chronic pain in later stages. Patients will be assessed at three time points: the first day after surgery, the 7th day after surgery, and 1 month. The information we obtain will offer healthcare providers, from multiple hospitals, information about the care they provide to their patients for pain while patients are still in hospital and insights as to how the care might be improved, once they are discharged.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 1000
Est. completion date December 31, 2030
Est. primary completion date December 31, 2030
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Adult 2. On the first post-operative day and back on the ward for at least 6 hours 3. Gives consent for assessment at 3-time points Exclusion Criteria: 1. The patient is unable to communicate 2. The patient is cognitively impaired 3. The patient is asleep 4. The patient is too ill or in too much pain and does not wish to be interviewed 5. The patient does not wish to fill in the outcomes questionnaire

Study Design


Locations

Country Name City State
Germany Jena University Hospital Jena
Mexico Hospital General de Chihuahua Salvador Zubirán Anchondo El Bajo Chihuahua
Mexico Hospital San Javier Guadalajara Guadalajara
Mexico Hospital Aranda de La Parra (Leon Guanajuato) León Guanajuato
Mexico Centro Nacional SIGLO XXI (IMSS) Mexico City
Mexico Hospital Angeles Interlomas CDMX Mexico City
Mexico Hospital Central Militar Mexico City Cdmx
Mexico Hospital de traumatologia y Ortopedia Lomas Verdes (IMSS) Mexico City
Mexico Hospital fundación Medica Sur Mexico City
Mexico Hospital General de Villacoapa (IMSS) Mexico City
Mexico Hospital Ruben Leñero Mexico City
Mexico Instituto Nacional de Cancerología Mexico City
Mexico Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán Mexico City
Mexico Instituto Nacional de Enfermedades Respiratorias Cosio Villegas (INER) Mexico City
Mexico Hospital Angeles Puebla Puebla
Mexico Hospital Central Morones Prieto San Luis Potosi San Luis Potosi

Sponsors (16)

Lead Sponsor Collaborator
Jena University Hospital Centro Medico Nacional Siglo XXI IMSS, Fundación Clínica Médica Sur, Hospital Angeles Lomas, Hospital Angeles Puebla, Hospital Aranda de La Parra (Leon Guanajuato), Hospital Central "Dr. Ignacio Morones Prieto", Hospital Central Militar, Hospital de Traumatología y Ortopedia Lomas Verdes, Hospital General de Chihuahua - Dr. Salvador Zubirán Anchondo, Hospital General Dr. Ruben Leñero, Hospital General Regional Número 2 Dr. Guillermo Fajardo Ortiz, Hospital San Javier Guadalajara, Instituto Nacional de Cancerologia de Mexico, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Instituto Nacional de Enfermedades Respiratorias

Countries where clinical trial is conducted

Germany,  Mexico, 

Outcome

Type Measure Description Time frame Safety issue
Other Exploratory regression analysis for improving understanding of pain interference on day 7 after surgery Exploratory regression analysis for pain interference on postoperative day 7 (BPI-PITS, dependent variable), demographic variables, perioperative treatment variables and patient-reported outcomes (International Pain Out Questionnaire) from the first post-operative day (POD1). First postoperative day and postoperative day 7
Other Exploratory regression analysis for improving understanding of pain intensity on postoperative day 7. Exploratory regression analysis for pain intensity on postoperative day 7 (BPI-PSVS, dependent variable). Independent variables will include demographic variables, perioperative treatment variables and patient-reported outcomes obtained on the first postoperative day (POD1) First postoperative day and postoperative day 7
Other Exploratory regression analysis for improving understanding of pain intensity at POM1 Exploratory regression analysis for pain intensity at POM1 (BPI-PSVS, dependent variable). Independent variables will include: demographic variables, perioperative treatment variables and patient reported outcomes (International Pain Out Questionnaire) from the first postoperative day (POD1). First postoperative day and 1 month after surgery
Primary The difference in pain interference scores between postoperative day 7 (POD7) and 1 month after surgery (POM1). We will assess whether pain-related functional impairment on postoperative day 7 is associated with functional pain-related impairment 1 month after surgery. Functional pain impairment will be assessed using the BPI short-form questionnaire and calculated as a Pain Interference Total Score (PITS) from the 7 interference questions in the BPI. Patients will be allocated to groups of no (PITS=0)/mild-(PITS=1-2)/ moderate /(PITS=2-5) and severe interference (PITS>5). Mean scores of the 2 domains within the functional items, physical interference (general activity, walking ability, and work) and effective interference (mood, enjoyment of life, and relations with other persons) will also be calculated. Sleep will addressed separately as it does not improve psychometric properties of the BPI interference scale. This methodology has been used in another PAIN OUT study, evaluating function at 6 months after surgery (Stamer et al, Pain. 2019 Aug;160(8):1856-1865). 7th day after surgery (POD7) and 1 Month (M1) after surgery
Primary The number of patients with high pain interference on the 7th day after surgery (POD7). Number of patients with high pain interference at postoperative day 7 (POD7, BPI-PITS >5). Day 7 after surgery
Secondary Differences in pain severity (BPI-PSVS, pain severity scale) between postoperative day 7 and 1 month after surgery (POM1). We will use the pain severity variables in the BPI to assess pain on postoperative day 7 compared to Month 1 after surgery. Day 7 after surgery and Month 1 after surgery
Secondary The differences in pain interference (BPI-PITS) between surgical disciplines on postoperative day 7. This will be a cohort of patients undergoing surgeries from different disciplines. We anticipate that median pain interference scores will not differ between the disciplines. Day 7 after surgery
Secondary The differences in pain interference (BPI-PITS) between surgical disciplines at month 1 after surgery. This will be a cohort of patients undergoing surgeries from different disciplines. We anticipate that median pain interference scores will not differ between the disciplines. 1 Month after surgery
Secondary The difference in the number of patients with signs of neuropathy on postoperative day 7 between the surgical disciplines. The difference in the number of patients with signs of neuropathy on postoperative day 7 (DN2 score = 3/7) between the surgical disciplines.
Neuropathy will be screened for using the 'Douleur Neuropathique en 2 Questions' (DN2) . Neuropathy is indicated for a score of >3/7 items in the questionnaire (Beloeil et al Early postoperative neuropathic pain assessed by the DN4 score predicts an increased risk of persistent postsurgical neuropathic pain. Eur J Anesthesiology 2017;34:652-7).
Day 7 after surgery
Secondary The difference in the number of patients with signs of neuropathy at 1 month after surgery (POM1) between the surgical disciplines. The difference in the number of patients with signs of neuropathy at POM1 (DN2 score = 3/7) between the surgical disciplines. 1 Month after surgery
Secondary Differences in pain interference scores between patients with vs without signs of neuropathy on postoperative day 7 Differences in pain interference (BPI-PITS) between patients with vs. without signs of neuropathy (DN2 score = 3/7) on postoperative day 7. Day 7 after surgery
Secondary Differences in pain interference (BPI-PITS) between patients with vs. without signs of neuropathy (DN2 score = 3/7) at POM1. Differences in pain interference (BPI-PITS) between patients with vs. without signs of neuropathy (DN2 score = 3/7) at POM1. 1 Month after surgery
Secondary Differences in pain severity between patients with vs without signs of neuropathy at POM1 Differences in pain severity (BPI-PSVS) between patients with vs. without signs of neuropathy (DN2 score = 3/7) at POM1. 1 Month after surgery
Secondary Assess the difference in the number of patients taking analgesics o POD7 vs POD1. The difference in the number of patients taking analgesics between postoperative day 7 and POM1. Patients will be asked if they are taking an analgesic at both time points. Day 7 after surgery and 1 Month after surgery
See also
  Status Clinical Trial Phase
Completed NCT05480111 - The Role of Quadratus Lumborum Blocks Following Minimally Invasive Hysterectomy Phase 4
Completed NCT06129305 - Erector Spina Muscle Distance From the Skin at Different Thoracal Elevations
Completed NCT04401826 - Micro-surgical Treatment of Gummy Smile N/A
Recruiting NCT04020133 - the Role of Popliteal Plexus Block in Pain Management After Anterior Cruciate Ligament Reconstruction. N/A
Completed NCT03023462 - Efficacy of an Anterior Quadratus Lumborum Block vs. a TAP-block for Inguinal Hernia Repair N/A
Completed NCT03652103 - Efficiency of Erector Spinae Plane Block For Patients Undergoing Percutaneous Nephrolithotomy Phase 4
Completed NCT03546738 - Spinal Cord Burst Stimulation for Chronic Radicular Pain Following Lumbar Spine Surgery N/A
Withdrawn NCT03528343 - Narcotic vs. Non-narcotic Pain Regimens After Pediatric Appendectomy Phase 1/Phase 2
Terminated NCT03261193 - ITM + Bupivacaine QLB vs. ITM + Sham Saline QLB for Cesarean Delivery Pain Phase 3
Completed NCT02525133 - Phase 3 Study of Efficacy and Safety of the XaraColl® Bupivacaine Implant After Hernioplasty Phase 3
Completed NCT03244540 - Regional Analgesia After Cesarean Section Phase 4
Enrolling by invitation NCT05316168 - Post Operative Pain Management for ACL Reconstruction Phase 3
Recruiting NCT04130464 - Intraperitoneal Infusion of Analgesic for Postoperative Pain Management Phase 4
Enrolling by invitation NCT04574791 - Addition of Muscle Relaxants in a Multimodal Analgesic Regimen for Analgesia After Primary Total Knee Arthroplasty N/A
Completed NCT04526236 - Influence of Aging on Perioperative Methadone Dosing Phase 4
Completed NCT04073069 - Scalp Infiltration With Diprospan Plus Ropivacaine for Postoperative Pain After Craniotomy in Adults Phase 4
Recruiting NCT05351229 - Intrathecal Morphine for Analgesia in Video-assisted Thoracic Surgery Phase 4
Enrolling by invitation NCT05543109 - Ultrasound Guided Psoas Compartment Block vs Suprainguinal Fascia Iliaca Compartment Block N/A
Completed NCT05346588 - THRIVE Feasibility Trial Phase 3
Completed NCT04919317 - Combination Dexamethasone and Bupivacaine Pain Control in Reduction Mammaplasty Phase 2